SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
SCYNEXIS (NASDAQ: SCYX), a biotechnology company focused on developing treatments for drug-resistant infections, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Conference. The company's senior leadership team will deliver an in-person presentation on September 10, 2025, from 10:30 AM to 11:00 AM ET in New York. One-on-one meetings with management will also be available through H.C. Wainwright representatives.
SCYNEXIS (NASDAQ: SCYX), azienda biotecnologica specializzata nello sviluppo di terapie per infezioni resistenti ai farmaci, ha annunciato la sua partecipazione al 27° Annual Global Conference di H.C. Wainwright. Il team di vertice terrà una presentazione in presenza il 10 settembre 2025, dalle 10:30 alle 11:00 ET a New York. Saranno inoltre disponibili incontri individuali con il management tramite i rappresentanti di H.C. Wainwright.
SCYNEXIS (NASDAQ: SCYX), una compañía biotecnológica centrada en desarrollar tratamientos para infecciones resistentes a medicamentos, anunció su participación en la 27ª Conferencia Global Anual de H.C. Wainwright. El equipo directivo ofrecerá una presentación presencial el 10 de septiembre de 2025, de 10:30 a 11:00 ET en Nueva York. También estarán disponibles reuniones individuales con la dirección a través de los representantes de H.C. Wainwright.
SCYNEXIS (NASDAQ: SCYX), 약물 내성 감염 치료제 개발에 주력하는 생명공학 기업이 H.C. Wainwright 제27회 연례 글로벌 콘퍼런스에 참가한다고 발표했습니다. 회사의 최고 경영진이 2025년 9월 10일 오전 10:30~11:00(동부시간) 뉴욕에서 대면 프레젠테이션을 진행합니다. 또한 H.C. Wainwright 대표를 통해 경영진과의 1:1 미팅도 제공됩니다.
SCYNEXIS (NASDAQ: SCYX), une société biotechnologique axée sur le développement de traitements contre les infections résistantes aux médicaments, a annoncé sa participation à la 27e conférence annuelle mondiale de H.C. Wainwright. L'équipe de direction présentera en personne le 10 septembre 2025, de 10h30 à 11h00 ET à New York. Des rendez-vous individuels avec la direction seront également proposés via les représentants de H.C. Wainwright.
SCYNEXIS (NASDAQ: SCYX), ein Biotechnologieunternehmen, das sich auf die Entwicklung von Therapien gegen medikamentenresistente Infektionen konzentriert, hat seine Teilnahme an der 27. jährlichen Global Conference von H.C. Wainwright angekündigt. Das Führungsteam des Unternehmens wird am 10. September 2025 von 10:30 bis 11:00 Uhr ET in New York eine persönliche Präsentation halten. Einzelgespräche mit dem Management sind ebenfalls über die Vertreter von H.C. Wainwright verfügbar.
- None.
- None.
JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Scynexis senior leadership team will participate in the H.C. Wainwright 27th Annual Global Conference.
Date: Wednesday September 10, 2025
Format: In-person presentation and 1x1 meetings
Time: 10:30 a.m.-11:00 a.m. ET
Location: New York, NY
If you are interested in scheduling a 1x1 meeting, please reach out to your H.C. Wainwright representative.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. Additional antifungal assets from this novel class are currently in clinical, pre- clinical and discovery phases, including the compound SCY-247. For more information, visit www.scynexis.com.
CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com
FAQ
When is SCYNEXIS (SCYX) presenting at the H.C. Wainwright Conference 2025?
How can investors meet with SCYNEXIS management at the H.C. Wainwright Conference?
Where is the SCYNEXIS H.C. Wainwright Conference presentation taking place?
What type of company is SCYNEXIS (SCYX)?
